PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDupilumab
Dupixent(dupilumab)
Dupixent (dupilumab) is an antibody pharmaceutical. Dupilumab was first approved as Dupixent on 2017-03-28. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat asthma, atopic dermatitis, esophageal diseases, prurigo, and sinusitis. The pharmaceutical is active against interleukin-4 receptor subunit alpha.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Dupixent (discontinued: Dupixent)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Dupilumab
Tradename
Proper name
Company
Number
Date
Products
DupixentdupilumabRegeneron PharmaceuticalsN-761055 RX2017-03-28
4 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
dupixentBiologic Licensing Application2024-09-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atopic dermatitisEFO_0000274D003876L20
Agency Specific
FDA
EMA
Expiration
Code
dupilumab, Dupixent, Regeneron Pharmaceuticals, Inc.
2029-05-20Orphan excl.
Patent Expiration
No data
ATC Codes
D: Dermatologicals
D11: Other dermatological preparations in atc
D11A: Other dermatological preparations in atc
D11AH: Agents for dermatitis, excluding corticosteroids
D11AH05: Dupilumab
HCPCS
No data
Clinical
Clinical Trials
262 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DermatitisD003872L30.94913101752
Atopic dermatitisD003876EFO_0000274L204912101751
EczemaD004485L30.928871338
AsthmaD001249EFO_0000270J451497728
RhinosinusitisD00009682563312
Nasal polypsD009298J33143311
Eosinophilic esophagitisD057765EFO_0004232K20.023329
EsophagitisD004941HP_0100633K2012328
SinusitisD012852EFO_0007486J3212227
PolypsD011127EFO_0000662235
Show 6 more
Indications Phases 3
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients77
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ConjunctivitisD003231H1022
Colorectal neoplasmsD01517922
Nasopharyngeal neoplasmsD00930322
Pathologic processesD01033511
AnosmiaD00008658211
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDupilumab
INNdupilumab
Description
Dupilumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>6WG8:A|Dupilumab Fab heavy chain EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLY LQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGHHHHHH >6WG8:B|Dupilumab Fab light chain DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKI SRVEAEDVGFYYCMQALQTPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTQGTTSVTKSFNRGEC
Identifiers
PDB6WG8, 6WGB, 6WGJ, 6WGK, 6WGL
CAS-ID
RxCUI
ChEMBL IDCHEMBL2108675
ChEBI ID
PubChem CID
DrugBankDB12159
UNII ID420K487FSG (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
IL4R
IL4R
Organism
Homo sapiens
Gene name
IL4R
Gene synonyms
NCBI Gene ID
Protein name
Interleukin 4 receptor
Protein synonyms
Uniprot ID
Mouse ortholog
Variants
No data
Financial
Revenue by drug
$
£
Dupixent Sanofi
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Dupixent Regeneron Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,319 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
278,999 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use